A Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Moderate to Very Severe COPD (PERSIST COPD-2)
NCT07780656
This study is recruiting at 8 US sites in 5 states, according to its ClinicalTrials.gov record last updated .
Summary
The study primarily aims to demonstrate the superiority of GSK5784283 as an add-on therapy compared to placebo in reducing the annualized rate of moderate and severe chronic obstructive pulmonary disease (COPD) exacerbations.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Pulmonary Disease, Chronic Obstructive
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 3
- Ages
- 40 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- GlaxoSmithKline
- Last updated on ClinicalTrials.gov
- November 5, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Florida · 4
- GSK Investigational Site · Cape Coral, FL
- GSK Investigational Site · Greenacres City, FL
- GSK Investigational Site · Miami, FL
- GSK Investigational Site · Tampa, FL
New York · 1
- GSK Investigational Site · New York, NY
South Dakota · 1
- GSK Investigational Site · Rapid City, SD
Utah · 1
- GSK Investigational Site · West Point, UT
Washington · 1
- GSK Investigational Site · Spokane, WA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.